List of Excipients in API ELUXADOLINE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ELUXADOLINE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Allergan Inc | VIBERZI | eluxadoline | 61874-075 | CELLULOSE, MICROCRYSTALLINE | |
| Allergan Inc | VIBERZI | eluxadoline | 61874-075 | CROSPOVIDONE | |
| Allergan Inc | VIBERZI | eluxadoline | 61874-075 | FERRIC OXIDE RED | |
| Allergan Inc | VIBERZI | eluxadoline | 61874-075 | FERRIC OXIDE YELLOW | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ELUXADOLINE
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ELUXADOLINE drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
ELUXADOLINE drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
ELUXADOLINE drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ELUXADOLINE drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
ELUXADOLINE drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
ELUXADOLINE drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
ELUXADOLINE drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
ELUXADOLINE drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
ELUXADOLINE drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
ELUXADOLINE drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
ELUXADOLINE drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Allergan Inc | eluxadoline | 61874-075 |
| >Company | >Ingredient | >NDC |
ELUXADOLINE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch